Introduction
The dry age-related macular degeneration (AMD) market is becoming an important area of research as the global aging population increases and more patients face progressive vision loss. Dry AMD is the most common form of AMD and can range from early disease with few symptoms to advanced geographic atrophy (GA), where retinal cells are gradually lost.
For many years, treatment options for advanced dry AMD were limited to monitoring, lifestyle measures, nutritional support, and low-vision care. The treatment landscape began to change in 2023 when the U.S. Food and Drug Administration approved therapies designed to slow the progression of geographic atrophy.
These developments are encouraging further research into complement inhibition, photobiomodulation, oral therapies, gene therapy, and other approaches. Market growth is therefore being shaped by both rising disease burden and continued innovation.
Understanding the Dry AMD Market
Dry AMD develops when aging-related changes affect the macula, the central part of the retina responsible for detailed vision. Early and intermediate stages may involve drusen and changes in retinal pigment cells. In advanced disease, geographic atrophy can damage the retinal pigment epithelium, photoreceptors, and related tissues.
The growing number of older adults is creating a larger patient population that may require long-term monitoring and treatment. At the same time, better retinal imaging is helping physicians identify disease progression earlier.
The market also includes diagnostic technologies, pharmaceutical therapies, clinical research, and supportive vision services. This creates opportunities for companies developing both medicines and technologies that can improve disease management.
Emerging Treatments Are Changing the Landscape
Complement Inhibitors
One of the biggest developments in the dry AMD market has been the introduction of complement-targeting treatments for geographic atrophy.
Pegcetacoplan targets complement component C3 and was approved in the United States in 2023. Clinical trials found that treatment reduced the rate of geographic atrophy lesion growth compared with sham treatment.
Avacincaptad pegol, which targets complement component C5, was also approved in 2023 for geographic atrophy. Clinical research has shown a reduction in the growth rate of GA lesions, although treatment does not restore retinal tissue that has already been lost.
These therapies have created a new treatment category and may encourage further investment in complement biology.
Photobiomodulation
Photobiomodulation is another area attracting research interest. This approach uses specific wavelengths of light and is being studied for early and intermediate dry AMD. Research suggests that it may affect mitochondrial function and oxidative stress in retinal cells. However, additional clinical evidence is needed to establish its long-term benefits.
Key Research Trends
Research is moving beyond a single biological pathway. Scientists are examining inflammation, oxidative stress, retinal metabolism, neuroprotection, and visual-cycle activity.
Clinical studies are also exploring oral medicines, gene-based approaches, cell therapies, and other methods designed to protect retinal cells. The diversity of approaches shows how complex dry AMD can be.
Another important trend is the use of advanced retinal imaging. Technologies such as optical coherence tomography can help researchers measure structural changes and monitor treatment response. Better imaging may also support earlier identification of patients at higher risk of progression.
Organizations such as Root Analysis track developments across pharmaceutical and biotechnology markets, helping researchers and industry participants understand changing treatment pipelines and competitive activity.
Market Opportunities and Challenges
The expanding treatment pipeline creates opportunities for pharmaceutical companies, biotechnology firms, diagnostic developers, and research organizations. A larger diagnosed patient population could also increase demand for specialist eye care and monitoring.
However, challenges remain. Many emerging therapies require repeated administration, which can increase treatment burden. Safety monitoring is also important because some complement inhibitors have been associated with risks such as inflammation or conversion to neovascular AMD.
Access and reimbursement may also influence market adoption. New therapies must demonstrate meaningful clinical value while healthcare systems consider treatment costs and long-term patient needs.
Advances in drug discovery are also being observed across other therapeutic areas, including the Non-Small Cell Lung Cancer Market, where targeted and precision-based treatments continue to shape research strategies. These developments highlight the wider importance of innovative therapies across complex diseases.
Future Outlook
The future of the dry AMD market is likely to depend on the ability of researchers to slow disease progression while improving patient convenience and treatment durability. Current therapies primarily aim to reduce the rate of geographic atrophy growth rather than reverse existing retinal damage.
Future research may produce treatments that target multiple disease pathways at the same time. Earlier diagnosis, personalized monitoring, longer-lasting drug delivery, and improved imaging could further change how dry AMD is managed.
The pipeline may also expand as researchers learn more about genetic factors, complement activity, inflammation, and retinal cell health. This could create additional opportunities for new drug classes and technology-based interventions.
Conclusion
The dry age-related macular degeneration market is entering a period of significant development. The approval of complement inhibitors has introduced new treatment options for geographic atrophy, while photobiomodulation, oral therapies, gene therapy, and other approaches continue to be investigated.
Although important challenges remain around treatment effectiveness, safety, cost, and patient access, continued research is expanding the possibilities for dry AMD management. As clinical evidence grows and new technologies mature, the market is expected to remain an active area of pharmaceutical and biotechnology research.